Key result
Phospholamban ablation using the CRISPR/Cas9 system significantly improved median survival from 50 to 55 days in a severe murine heart failure model.
Why the study?
Does phospholamban ablation improve mortality and cardiac function in a murine heart failure model?
Does phospholamban ablation improve mortality and cardiac function in a murine heart failure model?
Phospholamban ablation using the CRISPR/Cas9 system significantly improved early mortality and cardiac function in a severe murine heart failure model.
Sarcoplasmic reticulum Ca2+-ATPase 2a (SERCA2a) and its inhibitory protein called phospholamban (PLN) are pivotal for Ca2+ handling in cardiomyocyte and are known that their expression level and activity were changed in the heart failure patients. To examine whether PLN inhibition can improve survival rate as well as cardiac function in heart failure, we performed PLN ablation in calsequestrin overexpressing (CSQ-Tg) mice, a severe heart failure model, using clustered regularly interspaced short palindromic repeat (CRISPR)/CRISPR-associated (Cas) system. According this method, generation rate of PLN wild type mice (PLN copy >0.95) and PLN homozygous knockout (KO) mice (PLN copy <0.05) were 39.1% and 10.5%, respectively. While CSQ overexpression causes severe heart failure symptoms and premature death, a significant ameliorating effect on survival rate was observed in PLN homozygous KO/CSQ-Tg mice compared to PLN wild type/CSQ-Tg mice (median survival days are 55 and 50 days, respectively). Measurement of cardiac function with cardiac catheterization at the age of 5 weeks revealed that PLN ablation improved cardiac function in CSQ-Tg mice without affecting heart rate and blood pressure. Furthermore, increases in atrial and lung weight, an index of congestion, were significantly inhibited by PLN ablation. These results suggest that PLN deletion would be a promising approach to improve both mortality and cardiac function in the heart failure.
No takes yet. Share an insight, caveat, or question.
Kaneko et al. (2016) studied Heart failure (murine model) (n=52). Phospholamban (PLN) ablation using CRISPR/Cas9 vs. PLN wild type (WT) was evaluated on Median survival days (p=0.04). Phospholamban ablation using the CRISPR/Cas9 system significantly improved median survival from 50 to 55 days in a severe murine heart failure model.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: